Geron (GERN) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3741631036

Cancer, Treatment, Myelodysplastic, Syndromes, Myelofibrosis, Inhibitor

Geron Corporation is a biopharmaceutical company that specializes in developing and commercializing innovative treatments for myeloid hematologic malignancies, which are a group of serious blood disorders.

The company's lead product candidate, imetelstat, is a telomerase inhibitor that has shown promising results in clinical trials. Telomerase is an enzyme that helps cancer cells to multiply and survive, so by inhibiting it, imetelstat can slow down the growth of cancer cells. Currently, imetelstat is in Phase 3 clinical trials, which is the final stage of testing before it can be approved for use in patients.

Geron is focusing on using imetelstat to treat two specific types of blood disorders: myelodysplastic syndromes (MDS) and myelofibrosis. MDS is a condition where the bone marrow fails to produce enough healthy blood cells, while myelofibrosis is a type of bone marrow cancer. Imetelstat has the potential to improve the treatment options for patients with these diseases, who often have limited and ineffective treatment options.

Geron Corporation was founded in 1990 and is headquartered in Foster City, California. The company has a strong commitment to advancing the treatment of myeloid hematologic malignancies and improving the lives of patients affected by these diseases. You can learn more about Geron Corporation and its mission on its website: https://www.geron.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Geron (GERN) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Geron (GERN) - Stock Price & Dividends

GERN Stock Overview

Market Cap in USD 2,307m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1996-06-30

GERN Stock Ratings

Growth 5y 51.5
Fundamental -
Dividend -
Rel. Performance vs Sector 4.08
Analysts 4.43/5
Fair Price Momentum 4.89 USD
Fair Price DCF -

GERN Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

GERN Growth Ratios

Growth 12m 62.33%
Growth Correlation 12m 17%
Growth Correlation 3m 54%
CAGR 5y 26.97%
CAGR/Mean DD 5y 1.08
Sharpe Ratio 12m 0.50
Alpha vs SP500 12m 39.45
Beta vs SP500 5y weekly 0.90
ValueRay RSI 92.95
Volatility GJR Garch 1y 74.73%
Price / SMA 50 26.49%
Price / SMA 200 89.49%
Current Volume 11441.1k
Average Volume 20d 15576.3k

External Links for GERN Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of GERN stocks?
As of June 15, 2024, the stock is trading at USD 4.87 with a total of 11,441,119 shares traded.
Over the past week, the price has changed by +6.10%, over one month by +32.34%, over three months by +178.29% and over the past year by +57.61%.
What are the forecast for GERN stock price target?
According to ValueRays Forecast Model, GERN Geron will be worth about 5.4 in June 2025. The stock is currently trading at 4.87. This means that the stock has a potential upside of +11.5%.
Issuer Forecast Upside
Wallstreet Target Price 6.1 24.6
Analysts Target Price 4.8 -0.82
ValueRay Target Price 5.4 11.5